Serum Institute of India has already manufactured 40 million doses of the Oxford-AstraZeneca COVID-19 vaccine.
SII has partnered with global pharma giant AstraZeneca and the Oxford University for COVID-19 vaccine - Covishield
Serum Institute of India (SII) is likely to submit the findings of COVID-19 clinical trial before the end of December. If the data is found satisfactory, the government may approve the Oxford-AstraZeneca coronavirus vaccine by the first week of January.
SII is expected to submit the final set of data before the subject expert committee in the next 10 days or so, people in the know told Business Standard.
Last week, the subject experts committee (SEC) constituted by the Drug Controller General of India (DCGI), sought more data from Serum Institute of India for further consideration of their emergency use authorisation applications for Covishield.
"After detailed deliberation, the committee recommended that the SII should submit the following data/information for updated safety data of Phase II/III clinical trial in the country, immunogenicity data from the clinical trial in UK and India and the outcome of the assessment of UK MHRA for grant of EUA," DCGI said.
SII’s Chief Executive Officer (CEO) Adar Poonawalla has said that India can start its initial vaccine roll out by January 2021. However, the company expects a full-fledged approval to come by March 2021. The Pune-based firm has already manufactured 40 million doses of the AstraZeneca vaccine.
Meanwhile, the government on December 14 released guidelines for COVID-19 vaccination drive. Vaccinating 100-200 people in each session per day, monitoring them for 30 minutes after administering the shots for any adverse event and allowing only one beneficiary at a time are among the guidelines issued by the Centre for the COVID-19 inoculation drive.
COVID Vaccine Intelligence Network (Co-WIN) system--a digitalised platform--will be used to track enlisted beneficiaries for the vaccination and anti-coronavirus vaccines on a real-time basis.
So far, India has recorded 99,06,165 confirmed COVID- 19 cases, including 1,43,709 deaths. A total of 94,22,636 patients have recovered, as per the latest data from the Union Health Ministry. There are 3,39,820 active cases in the country.
Source - MoneyControl
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.